# US 2015/0086619 A1 · Individualized cancer therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0086619 A1
- Document ID: US20150086619A1
- Status: Published application
- Kind: A1
- Application number: 14/535,789
- Filed: 2014-11-07
- Published: 2015-03-26
- Earliest claimed: 2005-11-18
- Assignees: Gradalis, Inc.
- Applicants: Gradalis, Inc.
- Inventors: David M. Shanahan; John J. Nemunaitis, I; Neil Senzer; Phillip B. Maples; Donald Rao
- Web page: https://patentgrep.com/patent/US20150086619A1

## CPC

- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- A61K 9/1273: Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
- A61K 9/513: {Organic macromolecular compounds; Dendrimers}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 35/00: Antineoplastic agents
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/575: for cancer
- G01N 33/57595: {involving intracellular compounds}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

In certain embodiments, the invention provides methods for treating cancer, comprising: obtaining a specimen of cancer tissue and normal tissue from a patient; extracting total protein; obtaining a protein expression profile; identifying over-expressed proteins; comparing the protein expression profile to a gene expression profile; identifying at least one prioritized protein target; designing a first RNA interference expression cassette; designing a first RNA interference expression cassette to modulate the expression of at least one gene encoding; incorporating the first cassette into a delivery vehicle; and providing a patient with an effective amount of the first delivery vehicle.

## Claims

### Claim 1

A method for treating cancer, comprising:
obtaining a specimen of cancer tissue and normal tissue from a patient;
extracting total protein and RNA from the cancer tissue and normal tissue;
obtaining a protein expression profile of the cancer tissue and normal tissue;
identifying over-expressed proteins in the cancer tissue;
comparing the protein expression profile to a gene expression profile;
identifying at least one prioritized protein target;
designing a RNA interference expression cassette to modulate the expression of at least one gene encoding the prioritized target protein;
incorporating the RNA interference expression cassette into a delivery vehicle; and
providing a patient with an effective amount of the delivery vehicle sufficient to treat the cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the normal tissue is extracted from an area in close proximity to the cancer tissue or from an area of the tissue of origin of the cancer tissue.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cancer and normal tissue is extracted using laser capture microdissection.

### Claim 4 (depends on 1)

The method of claim 1, wherein the protein expression profile is obtained using at least one of 2D DIGE and mass spectrometry; HPLC and mass spectroscopy; or using one or more microarrays.

### Claim 5 (depends on 1)

The method of claim 1, wherein the proteins are considered to be over-expressed if the proteins are found in the cancer tissue at higher levels than in the normal tissue.

### Claim 6 (depends on 1)

The method of claim 1, wherein the protein is overexpressed if they are at least two-fold higher in the cancer tissue than in normal tissue.

### Claim 7 (depends on 1)

The method of claim 1, wherein the RNA interference expression cassette encodes one or more bifunctional shRNA molecules, shRNA molecules, or siRNA molecules.

### Claim 8 (depends on 1)

The method of claim 1, wherein the delivery vehicle is selected from the group consisting of immunoliposomes, immunolipoplexes, small molecule targeted lipoplexes, RGD targeted nanoparticles, RGD targeted liposomes, nanoparticles, aptamers, dendrimers, chitosan, pegylated derivatives thereof, and oncolytic viral vectors.

### Claim 9 (depends on 1)

The method of claim 1, further comprising measuring whether the RNA interference expression cassette is capable of suppressing the expression of one or more genes that encode the at least one or more prioritized proteins in vitro prior to providing said delivery vehicle to a patient.

### Claim 10 (depends on 1)

The method of claim 1, further comprising the steps of:
measuring whether the at least one prioritized protein exhibits a reduced expression level after provision of the delivery vehicle to the patient; and
continuing treatment if the expression level of the prioritized protein target decreases or designing a second protein expression inhibitor selected from at least one prioritized protein target identified by connectivity to the prioritized protein.

### Claim 11 (depends on 1)

The method of claim 1, wherein the RNA interference expression cassette comprises a tumor-specific promoter.

### Claim 12 (depends on 1)

The method of claim 1, wherein the RNA interference expression cassette comprises a bi-functional short hairpin RNA that targets the RNA that expresses the prioritized proteins for degradation and sequestration.

### Claim 13 (depends on 1)

The method of claim 1, wherein the one or more RNA interference expression cassettes are provided to cancer cells via a delivery vehicle selected from the group consisting of immunoliposomes, immunolipoplexes, RGD targeted nanoparticles, RGD targeted liposomes, nanoparticles, aptamers, dendrimers, chitosan, pegylated derivatives thereof, and oncolytic viral vectors.

### Claim 14 (depends on 1)

The method of claim 1, further comprising the steps of:
extracting total protein and RNA from the treated cancer tissue;
identifying over-expressed proteins in the treated cancer tissue;
designing a second RNA interference expression cassette to modulate the expression of a second prioritized protein in the treated tissue;
incorporating the second cassette into a second delivery vehicle;
providing the previously treated patient with an effective amount of the second delivery vehicle in an amount sufficient to treat the cancer.

### Claim 15

A method for treating cancer, comprising:
obtaining a specimen of cancer tissue and normal tissue from a patient;
extracting total protein and RNA from the cancer tissue and normal tissue;
obtaining a protein expression profile of the cancer tissue and normal tissue;
identifying over-expressed proteins in the cancer tissue;
identifying at least one prioritized protein target by assessing connectivity of each over-expressed protein;
designing a first RNA interference expression cassette to modulate the expression of at least one gene encoding the prioritized target protein;
incorporating the first cassette into a first delivery vehicle; and
providing a patient with an effective amount of the first delivery vehicle sufficient to treat the cancer.

### Claim 16 (depends on 15)

The method of claim 15, wherein the normal tissue is extracted from an area in close proximity to the cancer tissue or from an area of the tissue of origin of the cancer tissue.

### Claim 17 (depends on 15)

The method of claim 15, wherein the cancer and normal tissue is extracted using laser capture microdissection.

### Claim 18 (depends on 15)

The method of claim 15, wherein the protein expression profile is obtained using at least one of 2D DIGE and mass spectrometry; HPLC and mass spectroscopy; or using one or more microarrays.

### Claim 19 (depends on 15)

The method of claim 15, wherein the proteins are considered to be over-expressed if the proteins are found in the cancer tissue at higher levels than in the normal tissue.

### Claim 20 (depends on 15)

The method of claim 15, wherein the protein is overexpressed if they are at least two-fold higher in the cancer tissue than in normal tissue.

### Claim 21 (depends on 15)

The method of claim 15, wherein the RNA interference expression cassette encodes one or more bifunctional shRNA molecules, shRNA molecules, or siRNA molecules.

### Claim 22 (depends on 15)

The method of claim 15, wherein the delivery vehicle is selected from the group consisting of immunoliposomes, immunolipoplexes, small molecule targeted lipoplexes, RGD targeted nanoparticles, RGD targeted liposomes, nanoparticles, aptamers, dendrimers, chitosan, pegylated derivatives thereof, and oncolytic viral vectors.

### Claim 23 (depends on 15)

The method of claim 15, further comprising the steps of:
measuring whether the at least one prioritized protein exhibits a reduced expression level after provision of the delivery vehicle to the patient; and
continuing treatment if the expression level of the prioritized protein target decreases; or designing a second protein expression inhibitor selected from at least a second prioritized protein target identified by connectivity to the prioritized protein, wherein the second prioritized protein target is an effector downstream from the first prioritized protein target.

### Claim 24 (depends on 15)

The method of claim 15, further comprising the steps of:
measuring whether the at least one prioritized protein exhibits a reduced expression level after provision of the delivery vehicle to the patient; and
continuing treatment if the expression level of the prioritized protein target decreases; or designing a second protein expression inhibitor selected from at least a second prioritized protein target identified by connectivity to the prioritized protein, wherein the second prioritized protein target is an upstream effector in the case of feedback loop of the first prioritized protein target.

### Claim 25

A method for treating cancer, comprising:
obtaining a specimen of cancer tissue and normal tissue from a patient;
extracting total protein and RNA from the cancer tissue and normal tissue;
obtaining a protein expression profile of the cancer tissue and normal tissue;
identifying over-expressed proteins in the cancer tissue;
comparing the protein expression profile to a gene expression profile;
identifying at least one prioritized protein target by assessing connectivity of each said over-expressed protein to other cancer-related or stimulatory proteins;
designing a first RNA interference expression cassette to modulate the expression of at least one gene encoding the prioritized target protein;
designing a first RNA interference expression cassette to modulate the expression of at least one gene encoding a protein of higher priority in the signaling pathway in which the first protein is a component;
incorporating the first cassette into a first delivery vehicle;
providing a patient with an effective amount of the first delivery vehicle;
extracting total protein and RNA from the treated cancer tissue;
identifying over-expressed proteins in the treated cancer tissue;
designing a second RNA interference expression cassette to modulate the expression of a second prioritized protein in the treated tissue;
incorporating the second cassette into a second delivery vehicle;
providing the previously treated patient with an effective amount of the second delivery vehicle;
identifying a novel protein signal following prior treatment with protein specific knockdown;
identifying a gene mutation provided by gene sequencing/microarray on assessment of other protein signals; and
identifying of a novel protein signal as a result of determination of the gene mutation and assessment of other protein signals.
